Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Schedule of Change in Accounts Receivable, Contract Assets and Liabilities (Details)

v3.23.1
Collaboration and Research Arrangements - Schedule of Change in Accounts Receivable, Contract Assets and Liabilities (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2023
USD ($)
Disaggregation Of Revenue [Line Items]  
Contract liabilities, Balance at Beginning of Period $ 4,330
Contract liabilities, Additions 104
Contract liabilities, Deductions 1,189
Contract liabilities, Balance at End of Period 3,245
Global Blood Therapeutics  
Disaggregation Of Revenue [Line Items]  
Contract liabilities, Balance at Beginning of Period 4,330
Contract liabilities, Additions 104
Contract liabilities, Deductions (1,189)
Contract liabilities, Balance at End of Period $ 3,245